Cargando…

Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin

Most patients with hepatocellular carcinoma (HCC) are in the middle or advanced stage at the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to verify whether deoxythymidylate kinase (DTYMK) increased in HCC and was an effective therapeutic target in HCC. The fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Fengze, Liu, Yuanyuan, Gong, Tingting, Pan, Qiuzhong, Xiang, Tong, Zhao, Jingjing, Tang, Yan, Chen, Hao, Han, Yulong, Song, Mengjia, Huang, Yue, Li, Han, Chen, Yuanyuan, Yang, Chaopin, Yang, Jieying, Wang, Qijing, Li, Yongqiang, He, Jia, Weng, Desheng, Peng, Ruiqing, Xia, Jianchuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602592/ https://www.ncbi.nlm.nih.gov/pubmed/34795209 http://dx.doi.org/10.1038/s41419-021-04375-3

Ejemplares similares

SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway
por: Yang, Jieying, et al.
Publicado: (2022)

Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma
por: Yang, Jieying, et al.
Publicado: (2023)

Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma
por: Yang, Chaopin, et al.
Publicado: (2023)

CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma
por: Huang, Yue, et al.
Publicado: (2022)

BMP9‐induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus‐associated hepatocellular carcinoma
por: Han, Yulong, et al.
Publicado: (2023)

Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer
por: Yang, Xinyi, et al.
Publicado: (2022)

CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype
por: Li, Han, et al.
Publicado: (2022)

DTYMK is essential for genome integrity and neuronal survival
por: Vanoevelen, Jo M., et al.
Publicado: (2021)

Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer
por: Song, Mengjia, et al.
Publicado: (2023)

Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma
por: Song, Mengjia, et al.
Publicado: (2020)

Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma
por: Song, Mengjia, et al.
Publicado: (2019)

Comprehensive analysis of DTYMK in pan-cancer and verification in lung adenocarcinoma
por: Zhang, Yue, et al.
Publicado: (2022)

The Impact of DTYMK as a Prognostic Marker in Colorectal Cancer
por: Aloliqi, Abdulaziz A., et al.
Publicado: (2023)

OTUD4-mediated GSDME deubiquitination enhances radiosensitivity in nasopharyngeal carcinoma by inducing pyroptosis
por: Di, Muping, et al.
Publicado: (2022)

Severe delayed pulmonary toxicity following PD‐L1–specific CAR‐T cell therapy for non‐small cell lung cancer
por: Liu, Heping, et al.
Publicado: (2020)

Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors
por: Zhao, Huihui, et al.
Publicado: (2022)

DTYMK Expression Predicts Prognosis and Chemotherapeutic Response and Correlates with Immune Infiltration in Hepatocellular Carcinoma
por: Guo, Yiwen, et al.
Publicado: (2021)

Comprehensive analysis of DTYMK for estimating the immune microenvironment, diagnosis, prognosis effect in patients with lung adenocarcinoma
por: Chen, Xi, et al.
Publicado: (2022)

Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT
por: Yang, Yan, et al.
Publicado: (2019)

MiR-148b-3p Regulates the Expression of DTYMK to Drive Hepatocellular Carcinoma Cell Proliferation and Metastasis
por: He, Guifang, et al.
Publicado: (2021)

Differential expression of enzymes in thymidylate biosynthesis in zebrafish at different developmental stages: implications for dtymk mutation-caused neurodegenerative disorders
por: Frisk, Junmei Hu, et al.
Publicado: (2022)

Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene
por: Ma, Haiqing, et al.
Publicado: (2010)

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial
por: Xu, Bushu, et al.
Publicado: (2023)

Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC
por: Wei, Yulong, et al.
Publicado: (2021)

Activation of Anti-tumor Immune Response by Ablation of HCC with Nanosecond Pulsed Electric Field
por: Xu, Xiaobo, et al.
Publicado: (2017)

HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway
por: Chen, Lu, et al.
Publicado: (2018)

Deoxythymidylate kinase (DTYMK) participates in cell cycle arrest to promote pancreatic adenocarcinoma progression regulated by miR-491-5p through TP53 and is associated with tumor immune infiltration
por: Bao, Wenguang, et al.
Publicado: (2023)

New techniques: a roadmap for the development of HCC immunotherapy
por: Jiang, Dizhi, et al.
Publicado: (2023)

TACE responser NDRG1 acts as a guardian against ferroptosis to drive tumorgenesis and metastasis in HCC
por: Tang, Bufu, et al.
Publicado: (2023)

Silencing circular RNA-friend leukemia virus integration 1 restrained malignancy of CC cells and oxaliplatin resistance by disturbing dyskeratosis congenita 1
por: Liu, Weipeng, et al.
Publicado: (2022)

Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin
por: Wang, Xiumei, et al.
Publicado: (2020)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
por: Song, Meng‐Jia, et al.
Publicado: (2021)

Levo-tetrahydropalmatine attenuates oxaliplatin-induced mechanical hyperalgesia in mice
por: Guo, Zhenggang, et al.
Publicado: (2014)

Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
por: Sun, Na, et al.
Publicado: (2020)

Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma
por: Pan, Qiuzhong, et al.
Publicado: (2023)

TRIB3 facilitates glioblastoma progression via restraining autophagy
por: Tang, Zhanbin, et al.
Publicado: (2020)

Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape
por: Ma, Yuanyuan, et al.
Publicado: (2023)

The Epigenetic Regulation of HCC Metastasis
por: Han, Tae-Su, et al.
Publicado: (2018)

Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2018)

Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell
por: Yang, Chaopin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tuiv2u7t0gvurgvqfsv4s548c6